

# The 8th Annual Meeting of the International Academy for Clinical Hematology (IACH)

October 9-11, 2025 – Paris, France & Online



## Faculty Disclosures Report

The IACH Meeting seeks to balance the important benefits of physician-industry relationships with the potential risk that the financial goals of the industry may conflict with the professional goals of IACH Meeting participants. In doing so, the IACH Meeting recognizes that it has a profound duty to its participants, the larger medical community and the public to ensure the integrity of all of its scientific, educational, and advocacy activities and materials.

### Educational Content Development

The IACH Meeting requires all Program members and any others in a position to control the educational content to disclose any commercial financial interests prior to the development of the educational content. A process of resolution of conflict of interest is used for those members who do have financial interests related to the development of the content.

### Presenters

The IACH Meeting considers financial relationships to create actual conflicts of interest when presenters have both a financial relationship with a commercial interest and the opportunity to affect the policy of the IACH Meeting of CME about the products or services of that commercial interest. The potential for Presenter to maintaining or increasing the value of the financial relationship with the commercial interest creates an incentive to influence the content of the CME – an incentive to insert commercial bias. All presenters of CME content should familiarize themselves with the policy of the IACH Meeting of CME based on the CME providers of the Meeting.

All IACH Meeting Faculty presenting CME are required to disclose the following prior to beginning their presentation:

- Any relevant financial relationships a CME presenter has had with manufacturers of commercial products or providers of commercial services within the past 12 months. The IACH Meeting defines "relevant" financial relationships as those with a commercial interest and the opportunity to affect the content of CME about the products or services of that commercial interest
- CME presenters who report they have no known relevant financial relationships to disclose will declare "No Financial Relationships"

### Financial Disclosure Codes

Type of affiliation / financial interest	Code
Honorarium / Lecture fees	H
Advisory Board	A
Consultant	C
Research Support	R
Speakers' Bureau	S
Other: <i>Written as stated on submitted form</i>	
Nothing to declare: <i>Written as said statement</i>	

### Disclosure Information

Financial interest disclosures from program members and others in a position for control content

**The 8th Annual Meeting of the International Academy for Clinical Hematology (IACH)**  
October 9-11, 2025 – Paris, France & Online



**Summary**

**Lionel Adès, France**

H BMS, AbbVie, Novartis  
R Servier, BMS, AbbVie

**Luca Arcaini, Italy**

H Roche  
S EUSA Pharma, Novartis, Kite, Beigene  
A Roche, Janssen-Cilag, Verastem, Incyte, EUSA Pharma, Celgene/BMS, Kite/Gilead, ADC Therapeutics, Novartis

**Farrukh Awan, USA**

C Loxo Oncology, Beigene, Dava Oncology, Astrazeneca, Genmab, Adaptive, BMS, AbbVie, Incyte, Miltenyi, Invivyd, Pierre Fabre, DMSC for Ascentage, Caribou Biosciences  
R Abbvie/Pharmacyclies

**Ali Bazarbachi, Lebanon**

H,R Roche, Janssen, BMS, Amgen, Takeda

**Didier Blaise, France**

*Nothing to declare*

**Côme Bommier, France**

H BeiGene  
C JnJ, BMS, Cureety, Novartis  
R Servier

**Uma Borate, USA**

H RUNXI Foundation  
A AbbVie, Genentech, Agios, Novartis, Blueprint, Astellas, Takeda, Kura, Servier  
Other Grants: AbbVie, Incyte, Jazz, Pfizer

**Eolia Brissot, France**

H,R Novartis, Astellas, Alexion, Jazz Pharmaceuticals, Kite/Gilead, MSD, Keocyt, Amgen, BMS, Pierre Fabre, Beigene, Servier

**Carmelo Carlo-Stella, Italy**

H ADC Therapeutics, AstraZeneca, Celgene/BMS, F. Hoffmann-La Roche, Gilead, Incyte, Janssen Oncology, Novartis, SOBI, MSD, AbbVie  
C ADC Therapeutics, Celgene/BMS, F. Hoffmann-La Roche, Janssen Oncology, Novartis, SOBI, Astra Zeneca, Gilead, AbbVie  
R ADC Therapeutics, F. Hoffmann-La Roche

**Julio Chavez, USA**

H AstraZeneca, Autolus, BeiGene, BMS, CRISPR, GenMab, Genentech, Kite/Gilead, Novartis  
C Lilly  
R GenMab, Merck, Kite/Gilead

**Fabio Ciceri, Italy**

*Nothing to declare*

**Thomas Cluzeau, France**

H Amgen, Novartis, Jazz  
C AbbVie, BMS, Daiichi, Servier

**The 8th Annual Meeting of the International Academy for Clinical Hematology (IACH)**  
October 9-11, 2025 – Paris, France & Online



**Roberto Crocchiolo**, Italy

*Nothing to declare*

**Antonio Curi**, Italy

*Nothing to declare*

**Moniek de Witte**, Netherlands

*Nothing to declare*

**Matteo Della Porta**, Italy

*Nothing to declare*

**Raynier Devillier**, France

H,R      Jazz Pharma, Medac, Incyte, Sanofi, Astellas, MSD, Takeda, Novartis, Neovii, Alexion

**Amy DeZern**, USA

C      BMS, Servier, Keros, Novartis

**Shannon Elf**, USA

*Nothing to declare*

**Naren Epperla**, USA

*Nothing to declare*

**Andrew Evans**, USA

H      Pharmacyclics, Novartis, Pfizer, CRISPR, Genentech

**Justin Ferdinandus**, Germany

H      Takeda Oncology, Roche Pharma

C      Pfizer Pharma

**Sebastian Giebel**, Poland

H      Amgen

**Anna Godfrey**, UK

H      Novartis

C      Novartis, Celgene/BMS, AOP Pharma

**Claire Harrison**, UK

A      AbbVie, APO, BMS, CTI, IMAGO, Incyte, Novartis, Galacteo, Geron, GSK, Incyte, Janssen, Keros, MSD, SOBI, Morphosys

R      Celgene(BMS), Constellation, GSK, Novartis

**Florian Heidel**, Germany

H,C      BMS, Novartis, AOP, Merck, GSK, AbbVie, Janssen, Kartos/Telios

R      BMS, Novartis, CTI

**Olivier Hermine**, France

*Nothing to declare*

**Ernst Holler**, Germany

*Nothing to declare*

**He Huang**, China

*Nothing to declare*

## The 8th Annual Meeting of the International Academy for Clinical Hematology (IACH)

October 9-11, 2025 – Paris, France & Online



### **Susanne Isfort, Germany**

H AbbVie, Novartis, AOP, GSK, Incyte, Janssen, Alexion, Roche, Mundipharma  
C Novartis, GSK  
E Medical School Hannover

### **Tania Jain, USA**

A BMS, Incyte, AbbVie, CTI, Kite, Cogent Biosciences, Blueprint Medicine, Telios, Protagonist Therapeutics, Galapagos, Tscan, Karyopharm, Morphosys, In8Bio  
R CTI, Kartos Therapeutics, Incyte, BMS, Tscan, Karyopharm Therapeutics

### **Shahram Kordasti, USA**

*Nothing to declare*

### **Jurgen Kuball, Netherlands**

R Novartis, Miltenyi Biotech  
Other Shareholder of Founders BV; Inventor on multiple patents dealing with gdTCR and the development of engineered immune cells

### **Marco Ladetto, Italy**

*Nothing to declare*

### **Nora Liebers, Germany**

H Beigene, Roche  
E University Hospital Düsseldorf

### **Nicola Maciocia, UK**

### **Florent Malard, France**

Honoraria from Sanofi, Novartis, BMS, AstraZeneca, Therakos, Priotera, MSD, Jazz Pharmaceutical

### **John Mascarenhas, USA**

C Incyte, Novartis, BMS, SOBI, AbbVie, GSK, Kartos, Geron, Karyopharm, Roche, PharmaEssentia, Italfarmco Spa, Disc, Blueprint Medicines, Keros, Galeto, MorphoSys, Sumitomo  
R Incyte, Novartis, BMS, Disc, Kartos, Karyopharm, SOBI, Ajax, PharmaEssentia, Italfarmco Spa, MorphoSys

### **Christine Mauz-Körholz, Germany**

R Merck

### **Donal McLornan, UK**

H GSK, Novartis  
C GSK

### **Mary Frances McMullin, UK**

*Nothing to declare*

### **Adam Mead, UK**

*Nothing to declare*

### **Ruben Mesa, USA**

C Incyte, Novartis, Sobi, GSK, Pharmaessentia, Telios, Kartos, Genentech

### **Mohamad Mohty, France**

*Nothing to declare*

## The 8th Annual Meeting of the International Academy for Clinical Hematology (IACH)

October 9-11, 2025 – Paris, France & Online



**Julia Montoro**, Spain

*Nothing to declare*

**Talha Munir**, UK

H AstraZeneca, BeiGene, Sobi, Lilly, Janssen, AbbVie  
C AbbVie, Janssen, AstraZeneca, BeiGene  
R AbbVie, Janssen

**Jessika Okosun**, UK

H Roche, BeiGene  
C Astra Zeneca, Genmab, Incyte  
R BeiGene, Genmab, Astra Zeneca

**Astrid Olsnes**, Norway

*Nothing to declare*

**Francesco Onida**, Italy

H Menarini Stemline

**Giogio Orofino**, Italy

*Nothing to declare*

**Simona Pagiluca**, France

*Nothing to declare*

**Laura Palomo**, Spain

*Nothing to declare*

**Francesco Passamonti**, Italy

H Novartis, BMS, AbbVie, GSK, AOP Orphan, Jazz, Menarini Stemline

**Naveen Pemmaraju**, USA

C,A AbbVie, BMS, CTI BioPharma, GSK, Immunogen, Incyte, JnJ, Karyopharm, Menarini-Stemline Group, Morphosys, OPNA, Pacylex, Protagonist, Sobi, Takeda  
R Sager Strong Foundation, United States DOD  
Other Board of Directors / Management: Dan's House of Hope

**Bethan Psaila**, UK

H GSK, Novartis, Incyte  
C Alethiomics, GSK, Incyte, Novartis, BMS  
R Alethiomics, Incyte

**Marco Raddi**, Italy

*Nothing to declare*

**Deepti Radia**, UK

*Nothing to declare*

**Andreas Reiter**, Germany

H,C,R AbbVie, AOP, Astra Zeneca, BMS, Blueprint, GSK, Incyte, Novartis

**Daniel Royston**, UK

C Ground Truth Labs Ltd

## The 8th Annual Meeting of the International Academy for Clinical Hematology (IACH)

October 9-11, 2025 – Paris, France & Online



**Annalisa Ruggeri, Italy**

H Kite

**Valeria Santini, Italy**

*Nothing to declare*

**Niocle Santoro, Italy**

*Nothing to declare*

**Guy Sauvageau, Canada**

Other Founder of ExCellThera, common share in ExCellThera chief scientific officer of ExCellThera

**Bipin Savani, USA**

*Nothing to declare*

**Christoph Schmid, Germany**

*Nothing to declare*

**Bart Scott, USA**

*Nothing to declare*

**Marie Sebert, France**

*Nothing to declare*

**Roni Shouval, USA**

C Incyte, Sanofi

**Maximilian Stahl, USA**

C Novartis, Kymera, Sierra Oncology, GSK, Rigel, BMS, Sobi, Syndax, Kura Oncology, Keros Pharmaceuticals

**Alexandros Spyridonidis, Greece**

*Nothing to declare*

**Arjan van de Loosdrecht, Netherlands**

*Nothing to declare*

**Umberto Vitolo, Italy**

H AbbVie, Astra Zeneca, Genmab, Gilead, Incyte, MSD, Roche, Sobi

C AbbVie, Genmab, Gilead, Incyte, Regeneron, Sobi

**Daniel Wiseman, UK**

H Geron, Epigenetix, Blueprint, Jazz, Novartis

R Astex

Other Sobi (Trial Data Monitoring Committee Chair)

**Amer Zeidan, USA**

H,C AbbVie, Akesobio, Agois, Amgen, Astellas, BioCryst, Beigene, Boehringer-Ingelheim, Celgene/BMS, Chiesi/Cornerstone biopharma, Daiichi Sankyo, Dr Reddy, Epizyme, Faron, Fibrogen, GSK, Glycomimetics, Genentech, Gilead, Geron, Janssen, Jasper, Karyopharm, Kyowa Kirin, Keros, Kura, Novartis, Notable, Orum, Otsuka, Pfizer, Regeneron, Rigel, Seattle Genetics, Shattuck Labs, Schrodinger, Syros, Syndax, Servier, Takeda, Treadwell, Taiho, Vincerx, Zentalis

R AbbVie, Amgen, Astex, BMS/Celgene, Geron, Kura, Novartis, Otsuka, Shattuck Labs, Syros

**Lin Pierre Zhao, France**

*Nothing to declare*